Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. For a clinical-stage biopharmaceutical issuer focused on neurodegenerative and endocrine diseases, these documents are a primary source of information on financial condition, capital raising, and material program decisions.
Current reports on Form 8-K are especially relevant for AMLX. Recent 8-K filings have covered quarterly financial results, underwritten public offerings of common stock, and key R&D updates such as the decision to discontinue the ORION program of AMX0035 in progressive supranuclear palsy after Phase 2b results did not show differences versus placebo. Other 8-Ks describe the entry into underwriting agreements for equity offerings and the intended use of proceeds, including avexitide commercial readiness, research and development, working capital, and other general corporate purposes.
Investors can also use this page to track registration statements and prospectus supplements referenced in 8-Ks, which outline the terms of offerings and the securities being issued, as well as ongoing reporting obligations that detail research and development focus, cash runway expectations, and risk factors tied to Amylyx’ pipeline programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly understand items such as results of operations, material program changes, or capital structure updates. Real-time ingestion from the SEC’s EDGAR system means new Amylyx filings, including 8-Ks and other periodic reports, appear promptly, while structured views of exhibits and key sections make it easier to locate information on topics like avexitide development, AMX0035, AMX0114, and AMX0318.
For those analyzing AMLX stock, this page serves as a focused hub for reviewing the company’s regulatory record, understanding how it communicates material events, and seeing how financing activities align with its clinical-stage strategy.
Amylyx Pharmaceuticals Co-CEO Justin B. Klee reported an automatic tax-related share sale. On 02/02/2026, he sold 15,500 shares of Amylyx common stock at a weighted average price of $14.685 per share to cover tax withholding tied to vesting restricted stock units.
After this transaction, Klee still beneficially owned 3,363,898 Amylyx shares directly. The filing notes the sales were required for tax withholding and were not made at his discretion, and that individual sale prices ranged from $14.510 to $14.760.
Justin B. Klee has filed a Rule 144 notice to sell 15,500 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $227,617, to be sold on or about 02/02/2026 on NASDAQ.
The filing states there are 3,363,898 shares of this class outstanding. The shares to be sold were acquired via vesting of 31,667 restricted stock units from the issuer on 02/02/2026. In the prior three months, Klee sold additional common shares in three transactions totaling several thousand shares.
AMLX filed a notice under Rule 144 for a planned sale of restricted shares. The filing covers the proposed sale of 3,448 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 50,515, on or about 02/02/2026 on NASDAQ. The issuer reports 144,693 shares of this class outstanding. The shares to be sold were acquired from the issuer on 02/02/2026 through the vesting of 9,167 restricted stock units, with no separate cash payment required.
This notice reports a planned sale under Rule 144 of 15,500 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $227,593. The issuer had 3,363,965 shares outstanding at the time noted.
The securities to be sold were acquired on 02/02/2026 through the vesting of 31,667 restricted stock units. Over the prior three months, the same holder sold additional common shares, including 136,193 shares on 01/15/2026, 7,715 shares on 01/06/2026, and 1,974 shares on 01/16/2026, for disclosed gross proceeds. The signer confirms they are not aware of undisclosed material adverse information about the issuer.
Amylyx Pharmaceuticals (AMLX) shareholder James M. Frates filed a Rule 144 notice for a planned sale of 3,557 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of 52,097 and 173,547 shares outstanding.
The shares relate to equity compensation: 10,000 common shares were acquired on 02/02/2026 through the vesting of restricted stock units from the issuer, with no separate cash payment. During the prior three months, Frates sold 3,326 common shares on 01/06/2026 for gross proceeds of 36,954. By signing, he represents that he is not aware of any undisclosed material adverse information about the issuer’s operations.
The Vanguard Group has filed a Schedule 13G reporting beneficial ownership of Amylyx Pharmaceuticals common stock. Vanguard reports beneficial ownership of 5,804,912 shares, representing 5.28% of the class as of the event date of 12/31/2025.
Vanguard has shared voting power over 698,623 shares and shared dispositive power over 5,804,912 shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business, not to change or influence control, and that Vanguard’s clients have rights to dividends and sale proceeds, with no single client holding more than 5%.
BlackRock, Inc. has filed an amended Schedule 13G reporting a significant ownership stake in Amylyx Pharmaceuticals, Inc. common stock as of 12/31/2025. BlackRock reports beneficial ownership of 7,783,648 shares, representing 7.1 % of Amylyx’s outstanding common stock.
The filing states that BlackRock has sole power to vote or direct the vote over 7,653,538 shares and sole power to dispose or direct the disposition of 7,783,648 shares, with no shared voting or dispositive power. The securities are described as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx.
Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported option exercises and related share sales. On January 15, 2026, he exercised 197,182 stock options at $7.57 per share and sold 136,193 shares of common stock at a weighted average price of $13.5895. On January 16, 2026, he exercised an additional 2,818 stock options at $7.57 per share and sold 1,974 shares at a weighted average price of $13.8293. A footnote states that shares were sold to cover option cost and tax obligations under a preset sales plan adopted on November 12, 2025. After these transactions, Cohen directly beneficially owned 3,379,465 shares of Amylyx common stock.
Amylyx Pharmaceuticals Co-Chief Executive Officer and director Justin B. Klee reported option exercises and related share sales. On January 15, 2026, he exercised stock options for 197,153 shares of common stock at an exercise price of $7.57 per share, then sold 136,193 shares at a weighted average price of $13.5827 per share. On January 16, 2026, he exercised options for an additional 2,847 shares at $7.57 and sold 1,995 shares at a weighted average price of $13.8853 per share. According to the footnotes, these sales were made to cover option cost and tax obligations under a preset sales plan adopted on November 12, 2025. After these transactions, Klee directly held 3,379,398 shares of Amylyx common stock.
AMLX filed a Rule 144 notice for a planned insider stock sale. The filing covers the proposed sale of 1,995 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $26,972.40 as of the filing details.
The shares to be sold were acquired on January 16, 2026 via an exercise of stock options paid in cash on the same date. The notice also lists prior sales of the issuer’s common stock during the past three months for the account of Justin Klee, including 136,193 shares sold on January 15, 2026 for gross proceeds of $1,849,860.26 and 7,715 shares sold on January 6, 2026 for gross proceeds of $85,589.44.